Search

Calcitonin gene-related peptide (CGRP) receptors are classified into CGRP subtype 1 (CGRP(1)) and CGRP subtype 2 (CGRP(2)) based on the affinity of the antagonist, human alpha (halpha)-CGRP(8-37). halpha-CGRP(8-37) antagonizes CGRP(1) receptor-mediated responses with high affinity (K(B) < 100 nM) and antagonizes CGRP(2) receptor-mediated responses with low affinity (K(B) > 1 microM). CGRP(2) receptors have been previously reported to mediate relaxation of large porcine coronary arteries because this action is antagonized with low affinity by halpha-CGRP(8-37). In the present study, we used reverse transcription-polymerase chain reaction, radioligand binding, and values from our previously reported isolated tissue experiments to compare the CGRP receptor in porcine coronary arteries with the porcine CGRP(1) receptor stably expressed in human embryonic kidney (HEK) 293 cells. We identified calcitonin receptor-like receptor and receptor activity modifying protein 1 mRNA in coronary arteries. We also found that the ligand binding characteristics of the CGRP receptor in coronary arteries and the cloned CGRP(1) receptor were highly similar. K(I) values for halpha-CGRP(8-37) were 6.6 and 5.7 nM in porcine coronary arteries and the cloned CGRP(1) receptor, respectively. The affinities (K(B)) of halpha-CGRP(8-37) and five other antagonists were 22- to 707-fold lower in functional experiments measuring relaxation of coronary arteries than in radioligand binding experiments. Despite this difference in absolute affinity values, there was a high correlation of the rank order of affinity for the antagonists determined by the two methods. Thus halpha-CGRP(8-37) antagonizes CGRP-induced relaxation of porcine coronary arteries with low affinity at the CGRP(1) receptor. Taken together, these data do not support the existence of the CGRP(2) receptor.

The molecular and pharmacological characteristics of muscarinic receptor subtypes in the rat parotid acinar cell line, PAR-C5, were determined and compared with native rat parotid glands to evaluate the PAR-C5 cell line as a model to study receptor-mediated secretion. Reverse transcription-polymerase chain reaction (RT-PCR) identified mRNAs for M(3), M(4), and M(5) receptor subtypes in both PAR-C5 cells and parotid glands. Specific [N-methyl-(3)H]scopolamine binding in PAR-C5 and parotid membranes was to a single class of sites with mean K(D) values of 0.38 and 0.64 nM, respectively. Binding affinities (K(I) values) of muscarinic receptor subtype-selective drugs were obtained in side-by-side experiments comparing PAR-C5 cells with parotid glands. Nonlinear regression analysis indicated that competition binding curves for drugs in PAR-C5 cells and parotid glands fit best to a one-site binding model. K(I) values (nM) in PAR-C5 cells and parotid glands, respectively, for atropine (1.0, 2.1), darifenacin (1.2, 2.0), 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) (2.9, 2.4), tripitramine (220, 180), pirenzepine (320, 720), and methoctramine (1400, 1700) were consistent with their known affinities at the M(3) receptor subtype. Affinities (K(B) values) of muscarinic receptor subtype-selective drugs for blocking methacholine-stimulated Ca(2+) mobilization were determined to show which subtype mediates Ca(2+)-dependent secretion in Fura-2-loaded PAR-C5 cells. K(B) values (nM) for atropine (0.44), 4-DAMP (0.38), pirenzepine (140), and methoctramine (320) for blocking Ca(2+) responses correlated well with their known affinities at the M(3) receptor (r(2) = 0.99). These results show that at the level of mRNA, receptor protein and function, PAR-C5 cells and parotid glands are similar, establishing PAR-C5 cells as an important model for muscarinic receptor-mediated secretion.

To investigate alpha1B-adrenoceptor function, we developed a phosphorothioate antisense oligodeoxynucleotide (AO) to inhibit the expression of the alpha1B-adrenoceptor subtype in DDT1 MF2 cells. We measured the cellular uptake of the AO and its effect on alpha1B-adrenoceptor mRNA expression, protein density, and coupling to phospholipase C. Cells treated with either a control oligodeoxynucleotide (CO) or medium alone served as control groups. Confocal microscopy demonstrated that DDT1 MF2 cells internalized carboxyfluorescein-labeled (FAM) AO within 30 min. Analysis of cellular lysates showed that approximately 50% of the intracellular FAM-AO was present as an intact 18-mer for up to 48 hr. Incubation of cells with AO for 48 hr decreased alpha1B-adrenoceptor density ([3H]prazosin Bmax) versus control groups by 12% (1 microM AO) and 72% (10 microM AO). In time course experiments, AO (10 microM) reduced alpha1B-adrenoceptor density by 28, 64, and 68% versus controls after 24, 48, and 72 hr of exposure, respectively. alpha1B-Adrenoceptor mRNA concentration (measured by RT-PCR) was reduced by 25% in cells treated for 48 hr with 10 microM AO versus controls. AO pretreatment (10 microM, 48 hr) reduced the maximum response to agonist-stimulated [3H]inositol phosphate accumulation. The maximal response of the full agonist norepinephrine was reduced by 30% after AO treatment, and by 73% for the partial agonist naphazoline. In contrast, AO did not affect histamine-stimulated total [3H]inositol phosphate accumulation. Thus, AO effectively reduced alpha1B-adrenoceptor subtype expression and function in vitro, suggesting a potential to selectively inhibit alpha1B-adrenoceptor function in vivo.

A genomic DNA library consisting of human DNA fragments about 18 kilobases long cloned in a bacteriophage lambda vector was found to contain a specific repeated DNA segment. The repeated sequence is present in greater than 95% of the genomic library, and selected clones contain at least two copies of the sequence. Our experiments indicate that this highly repetitive sequence (approximately 400,000 copies per haploid genome) is widely distributed in the human genome and is represented in the cytoplasmic polysomal mRNA. This sequence is homologous to the 300-base-pair Alu repeat family, the predominant repeat sequence in man.

The rise of air bubbles in five Newtonian fluids is compared for two different cases of bubble formation and release: (a) directly into the five homogeneous fluids and (b) directly into a layer of distilled water underlying each one of the five liquids. It was found in Case (b) that medium-sized bubbles rise steadily through the upper liquid with an enveloping water layer of variable thickness. The influence of this water layer on the trajectory, shape, and terminal velocity of bubbles is particularly significant in low viscosity upper phases. The resulting water mass transfer per bubble through the lower density upper phase depends on viscosity and was markedly greater for the higher viscosity fluids. The behavior and the nature of the detachment of the water layers from the larger size bubbles are also presented and discussed.

Three distinct alpha-1 adrenergic receptor subtypes (alpha-1a, alpha-1b and alpha-1d) have been identified through molecular cloning. Expression of alpha-1 adrenergic receptor mRNA has been detected in several tissues, but previous studies with Northern blot analysis or RNase protection assays have provided only semiquantitative information. Furthermore, the mRNA distribution of these subtypes in many rat tissues is unknown. In the present study, we quantified alpha-1a, alpha-1b and alpha-1d adrenergic receptor mRNA in 19 adult rat tissues through the use of reverse transcription (RT) and a competitive polymerase chain reaction (PCR). This procedure used internal cRNA standards as competitive templates that contained sequences complementary to the primers for alpha-1a, alpha-1b and alpha-1d adrenergic receptors and that differed in molecular size from the native sequences. Total RNA was harvested from 19 freshly dissected organs of the rat. The PCR products were labeled by inclusion of alpha-32P-dCTP in the PCR. After electrophoresis, ratios of competing to native radio-labeled products were used to interpolate the amount of native RNA originally present in each sample. The results revealed that the relative abundance of alpha-1a adrenergic receptor mRNA among various tissues was as follows: vas deferens > colon > or = stomach > or = cerebral cortex > heart > or = small intestine > or = testis > prostate. The relative rank order of alpha-1b adrenergic receptor mRNA expression was heart > or = cerebral cortex > liver, whereas that of alpha-1d adrenergic receptor mRNA was vas deferens > cerebral cortex > or = aorta > adrenal gland.(ABSTRACT TRUNCATED AT 250 WORDS)

alpha 1-Adrenoceptor subtypes mediate many of the actions of the renal nerve, but their locations along the nephron are unknown. We investigated the distribution of alpha 1-adrenoceptor subtype mRNA and protein in rat proximal tubules and medullary thick ascending limbs (MTAL) using reverse transcription combined with polymerase chain reaction (PCR) and radioligand binding methods. Complementary primers were designed to span cDNA sequences in each of the third intracellular loops of the rat alpha 1B- and alpha 1D-adrenoceptors. Expression of the mRNA of alpha 1B- and alpha 1D-adrenoceptors was first detected in total RNA from whole rat kidney, and the PCR product identity was confirmed by sequencing. Endogenous expression of alpha 1B- and/or alpha 1D-adrenoceptor mRNA was then investigated in microdissected segments of the rat proximal convoluted tubule (S2 segments) and the MTAL. mRNA was reverse-transcribed directly from permeabilized microdissected segments and the resulting cDNA was subjected to PCR with the alpha 1-adrenoceptor primers. In proximal convoluted tubules, amplification of both alpha 1B- and alpha 1D-adrenoceptor mRNA was observed. In MTAL segments, only alpha 1D-adrenoceptor mRNA was detected. We also measured receptor protein using [3H]prazosin in saturation and competition binding experiments. Proximal tubular membranes contained 3.3-fold more alpha 1-adrenoceptor than did MTAL membranes (163 +/- 21 versus 49 +/- 3 fmol/mg of protein). When the alkylating agent chloroethylclonidine (CEC) (10 microM, 10 min) was used to define alpha 1-adrenoceptor subtypes, proximal tubules were found to contain primarily CEC-insensitive (alpha 1A) sites (68 +/- 4%) and MTAL primarily CEC-sensitive sites (75 +/- 3%). Most [3H]prazosin binding sites (72 +/- 2%) in MTAL segments were also sensitive to the alkylating agent SZL-49, consistent with their identification as alpha 1D-adrenoceptors. In competition studies with the antagonists WB4101, 5-methylurapidil, and (+)-niguldipine, both high and low affinity sites were observed in proximal tubules. WB4101 interacted with only one site in MTAL membranes, intermediate in affinity between those sites found in proximal tubules. We conclude that reverse transcription-PCR is a useful method for demonstrating the expression of alpha 1-adrenoceptor subtypes in small amounts of tissue. Results from our experiments suggest that alpha 1A-, alpha 1B-, and alpha 1D-adrenoceptors are all expressed in proximal tubules and that alpha 1D-adrenoceptors are the primary alpha 1-adrenoceptor subtype expressed in MTAL. The distinct anatomical distribution of each of these adrenoceptor subtypes suggests that they serve different functions in the kidney.